Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
Open Access
- 2 October 2001
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 85 (7) , 939-943
- https://doi.org/10.1054/bjoc.2001.2031
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Capecitabine, an Oral Fluoropyrimidine Carbamate With Substantial Activity in Advanced Colorectal Cancer: Results of a Randomized Phase II StudyJournal of Clinical Oncology, 2000
- Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.1999
- Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast CancerJournal of Clinical Oncology, 1999
- [Phase I study of S-1. S-1 Study Group].1997
- Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulatorsAnti-Cancer Drugs, 1996
- Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. A randomized phase II study of the cancer and leukemia group BCancer, 1991
- Association of interleukin-2 therapy with staphylococcal bacteremiaCancer, 1991
- Continuous 5-Fluorouracil Infusion in Advanced Gastric CarcinomaAmerican Journal of Clinical Oncology, 1988
- Phase II Study of UFT in Patients With Advanced Non-Small Cell Lung CancerJapanese Journal of Clinical Oncology, 1986
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958